经皮冠状动脉介入治疗围手术期抗凝新视点

被引：9

作者：

周玉杰

闫振娴

机构：

[1] 首都医科大学附属北京安贞医院病房

来源：

心肺血管病杂志 | 2008年 / 01期

关键词：

经皮冠状动脉血管介入术; 围手术期; 抗凝;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：52 / 54+59 +59

页数：4

共 8 条

[1]

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors （SYNERGY） trial[J] . Harvey D. White,Neal S. Kleiman,Kenneth W. Mahaffey,Yuliya Lokhnygina,Karen S. Pieper,Karen Chiswell,Marc Cohen,Robert A. Harrington,Derek P. Chew,John L. Petersen,Lisa G. Be

[2]

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction[J] . Elliott M. Antman,David A. Morrow,Carolyn H. McCabe,Frank Jiang,Harvey D. White,Keith A.A. Fox,Divakar Sharma,Paul Chew,Eugene Braunwald.American Heart Journal . 2005 (2)

[3]

Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non–ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention[J] . Keith A.A Fox,Elliott M Antman,Marc Cohen,Frederique Bigonzi.The American Journal of Cardiology . 2002 (5)

[4]

Low–molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus *[J] . Dean J. Kereiakes,Gilles Montalescot,Elliott M. Antman,Marc Cohen,Harald Darius,James J. Ferguson,Cindy Grines,Karl R. Karsch,Neal S. Kleiman,David J. Moliterno,Phillippe-Gabriel Steg,Paul Teirstein,Frans Van de Werf,Lars Wallentin.American Heart Journal . 2002 (4)

[5]

A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention[J] . R.émi Choussat,Gilles Montalescot,Jean Philippe Collet,Eric Vicaut,Annick Ankri,Vanessa Gallois,G.érard Drobinski,Ivan Sotirov,Daniel Thomas.Journal of the American College of Cardiology . 2002 (11)

[6] Dalteparin in combination with abciximab during percutaneous coronary intervention [J].

Kereiakes, DJ ;

Kleiman, NS ;

Fry, E ;

Mwawasi, G ;

Lengerich, R ;

Maresh, K ;

Burkert, ML ;

Aquilina, JW ;

DeLoof, M ;

Broderick, TM ;

Shimshak, TM .

AMERICAN HEART JOURNAL, 2001, 141 (03) :348-352

[7] Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease [J].

Saito, Y ;

Wada, H ;

Yamamuro, M ;

Inoue, A ;

Shimura, M ;

Hiyoyama, K ;

Gabazza, EC ;

Isaka, N ;

Shiku, H ;

Takeya, H ;

Suzuki, K ;

Kumeda, K ;

Kato, H ;

Nakano, T .

AMERICAN JOURNAL OF HEMATOLOGY, 1999, 61 (04) :238-242

[8]

Comparison of the Pharmacokinetic Profiles of Three Low Molecular Mass Heparins – Dalteparin, Enoxaparin and Nadroparin – Administered Subcutaneously in Healthy Volunteers （Doses for Prevention of Thromboembolism）[J] . Thrombosis and Haemostasis . 1995 (04)

← 1 →